menu
    • menu
    [{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhaled Powder in Capsule","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Platelet aggregation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Liquidia Corporation \/ United Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia Corporation \/ United Therapeutics"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Pharmosa Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23000000000000001,"dosageForm":"Suspension for Inhalation","sponsorNew":"Liquidia Corporation \/ Liquidia Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia Corporation \/ Liquidia Corporation"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.10000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Liquidia Corporation \/ HealthCare Royalty","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia Corporation \/ HealthCare Royalty"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Liquidia Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Liquidia Corporation \/ Liquidia Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia Corporation \/ Liquidia Corporation"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Pharmosa Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Liquidia Corporation","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Liquidia Corporation \/ Liquidia Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Liquidia Corporation \/ Liquidia Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Liquidia Corporation

    Menu

    Liquidia Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Pharmosa Biopharm

                            Deal Size : $161.2 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Pharmosa Biopharm Expands Liquida Collaboration for Smart Nebulizers

                            Details : The agreement aims for the development and commercialization of L606, an inhaled, sustained-release formulation of treprostinil being evaluated for the treatment of PAH and PH-ILD.

                            Brand Name : L606

                            Molecule Type : Small molecule

                            Upfront Cash : $3.5 million

                            October 04, 2024

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Pharmosa Biopharm

                            Deal Size : $161.2 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Pharmosa Biopharm

                            Deal Size : $225.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil P...

                            Details : Liquidia will be responsible for development, regulatory and commercial activities of L606, an inhaled, sustained-release formulation of treprostinil being evaluated for treating PAH and pulmonary hypertension associated with interstitial lung disease, i...

                            Brand Name : L606

                            Molecule Type : Small molecule

                            Upfront Cash : $10.0 million

                            June 28, 2023

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Pharmosa Biopharm

                            Deal Size : $225.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : HealthCare Royalty

                            Deal Size : $100.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Liquidia Enters into a Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

                            Details : Liquidia intends to use the proceeds to fund the potential launch of Yutrepia, an inhaled dry powder formulation of treprostinil, upon final regulatory approval by the U.S. FDA and to support the continued clinical development of Yutrepia.

                            Brand Name : Yutrepia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 09, 2023

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : HealthCare Royalty

                            Deal Size : $100.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : United Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

                            Details : YUTREPIA/Tyvaso (treprostinil) inhalation powder, is an investigational, inhaled dry powder formulation of treprostinil delivered through a proven, convenient, palm-sized device for the treatment of pulmonary arterial hypertension.

                            Brand Name : Tyvaso

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 19, 2022

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : United Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder

                            Details : YUTREPIA is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability in adult patients. Tentative approval indicates that YUTREPIA has met all regulatory standards required for approval.

                            Brand Name : Yutrepia

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 08, 2021

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmo...

                            Details : LIQ861 (treprostinil) Inhalation Powder and act as platelet aggregation, which being evaluated for the treatment of patients with pulmonary arterial hypertension.

                            Brand Name : LIQ861

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 10, 2021

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hype...

                            Details : The patent is expected to cover methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.

                            Brand Name : LIQ861

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 28, 2020

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual M...

                            Details : New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL)

                            Brand Name : LIQ861

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 05, 2020

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Liquidia Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : RareGen

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH

                            Details : Through the acquisition, RareGen attains the right to to commercialize Liquidia’s lead product candidate in Pulmonary Arterial Hypertension (PAH), LIQ861, an inhalation dry powder formulation of treprostinil that is produced using Liquidia's PRINT® Te...

                            Brand Name : LIQ861

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 29, 2020

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : RareGen

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth